LianBio
LianBio’s aim is to catalyze the development and accelerate availability of ‘paradigm-shifting’ medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries.
The Sino-American biotech was founded by the privately-owned hedge fund sponsor Perceptive Advisors.
In November 2020, LianBio entered into a collaboration with US pharma giant Pfizer, aimed at developing and commercializing transformative pharmaceutical products in Greater China.
Latest LianBio News & Features
8 December 2023
2 December 2023
24 October 2023
20 December 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze